Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Atabecestat in Early Alzheimer's Disease
NCT02406027Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Primary completion
- Jun 2018
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of atabecestat in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Started Jul 2015; status: terminated.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02406027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02406027.